指南与共识泌尿生殖技术与安全

EAU-EANM-ESTRO-ESUR-ISUP-SIOG前列腺癌指南第二部分-2024更新:复发性和转移性前列腺癌的治疗

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
指南 / 共识 · Eur Urol · 2024-04-29

该指南由EAU、EANM、ESTRO、ESUR、ISUP和SIOG联合更新,基于2020至2023年文献综述和系统评价,为复发、转移及去势抵抗性前列腺癌的治疗提供推荐并标注推荐强度。关键内容包括原发治疗后复发风险分层可能指导挽救治疗决策,以及新型治疗选择如雄激素受体靶向药物、PARP抑制剂和基于前列腺特异性膜抗原的治疗已可用于转移性前列腺癌患者。

要点

  • 原发治疗后复发风险分层可能指导挽救治疗决策。
  • 转移性前列腺癌可用雄激素受体靶向药物、ARTA联合化疗、PARP抑制剂及其联合方案。
  • 基于前列腺特异性膜抗原的治疗已成为转移性前列腺癌的新选择。

核心结论

  • 复发、转移及去势抵抗性前列腺癌的证据正在快速演变,指南体现了前列腺癌管理的多学科性质。

研究设计与样本

  • 该指南由EAU、EANM、ESTRO、ESUR、ISUP和SIOG联合制定,基于2020至2023年新数据的文献综述进行更新,并在系统评价证据的基础上为每条推荐添加推荐强度。

诊断标准与关键数值

  • 原发治疗后复发风险分层可能指导挽救治疗决策。
  • 雄激素受体靶向药物、ARTA联合化疗、PARP抑制剂及其联合方案、基于前列腺特异性膜抗原的治疗已可用于转移性前列腺癌患者。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines.

METHODS: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence.

KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/).

PATIENT SUMMARY: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024. PMID: 38688773. doi:10.1016/j.eururo.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。